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Abstract:  AcrAB-TolC is the major multidrug efflux system in Enterobacteriaceae 
recognizing structurally unrelated molecules including antibiotics, dyes, and detergents. 
Additionally, in Escherichia coli it mediates resistance to bile salts. In the plant pathogen 
Erwinia amylovora AcrAB-TolC is required for virulence and phytoalexin resistance. 
Exchange analysis of AcrAB-TolC was conducted by complementing mutants of both 
species defective in acrB or tolC with alleles from either species. The acrB and tolC 
mutants exhibited increased susceptibility profiles for 24 different antibiotics. All 
mutants were complemented with acrAB or tolC, respectively, regardless of the 
taxonomic origin of the alleles. Importantly, complementation of E. amylovora mutants 
with respective E. coli genes restored virulence on apple plants. It was concluded that 
AcrAB and TolC of both species could interact and that these interactions did not yield in 
altered functions despite the divergent ecological niches, to which E. coli and E. 
amylovora have adopted.   
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1. Introduction 
Rising levels of bacterial multidrug resistance are an increasing problem in the treatment of 
infectious diseases. This phenotype is often associated with the expression of multidrug efflux (MDE) 
transporters, which export drugs out of the cell. The involved proteins belong to five well-
characterized families: the ATP-binding cassette (ABC) family, the major facilitator superfamily 
(MFS), the resistance-nodulation-cell division (RND) superfamily, the small multidrug resistance 
(SMR) family, and the multidrug and toxic compound extrusion (MATE) family [1]. Efflux by 
transporters of the MFS, RND, SMR, and MATE families is driven by proton (or sodium) motive 
force while ATP hydrolysis drives efflux in ABC transporters [2-5].  
RND-type transporters are widespread in Gram negative bacteria. In these efflux pumps, an outer 
membrane protein of the TolC family co-operates with both, an energized inner membrane translocase 
typically comprising a proton anti-porter and an adaptor protein located in the periplasmic space, thus 
forming a tripartite efflux system [2,4]. A remarkable feature of these efflux systems is the wide range 
of substrates that are recognized by individual pumps [6-7]. 
Escherichia coli, a member of Enterobacteriaceae, is one of the best and most thoroughly studied 
bacterial species. Some E. coli strains live as harmless commensals in the human intestines while other 
strains are pathogenic causing diseases and high mortality in humans [8]. AcrAB-TolC of E. coli is the 
best characterized RND efflux pump and has emerged as the principal structural and biochemical 
model system. The anti-porter AcrB and the membrane fusion adaptor AcrA form a translocase unit 
that interacts with the outer membrane protein TolC thus comprising a contiguous protein complex 
spanning the bacterial cell envelope and enabling drug efflux [9-10].  
AcrAB-TolC mediates resistance towards a wide variety of hydrophobic and amphiphilic 
compounds including bile salt, detergents, dyes, and antimicrobial agents [10]. Respective alleles of 
different gram-negative bacteria show a high degree of similarity and their deduced amino acid 
sequences are homologous [11-12]. The acrAB loci are regulated by members of TetR family of 
transcriptional repressors named AcrR. The acrR gene is located 141 bp upstream of the acrAB locus 
and is divergently transcribed [13]. AcrB is of particular interest since it mediates substrate specificity 
of the tripartite MDE pump towards a wide range of structurally diverse substances [14]. AcrAB 
recruits the separately expressed outer membrane protein TolC to extrude substrates from the inner 
membrane or the cytoplasm without any substrate accumulation in the periplasmic   
space [15].  
Homologues of E. coli TolC have been identified in numerous Gram-negative bacteria. Different 
AcrAB-like transport systems have evolved in E. coli and all share TolC as outer membrane partner 
[16-18]. The same was found for Klebsiella pneumoniae where AcrAB homologues specifically 
interact with the TolC-like outer membrane protein KocC, and the respective genes are not co-
transcribed [19]. In contrast, in other gram-negative bacteria individual TolC-like channels are often 
unique for a given RND-type transporter and their genes are consequently co-expressed in the same 
gene cluster as the RND-type pumps such as in the case of the oprJMN cluster in 
Pseudomonas aeruginosa [20-21] or the mtrRCDE cluster in Neisseria gonorrhoeae [22]. In bacterial 
species other than E. coli, the functions attributed to TolC are not linked to a single tolC allele but are 
distributed among various tolC homologues [23]. Int. J. Mol. Sci. 2009, 10                 
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Comparative genome analyses revealed high numbers of MDE pumps in soil or plant-associated 
bacteria [24]. Plants produce an array of diverse secondary metabolites that have antimicrobial 
activities including preformed so-called phyto-anticipants and phytoalexins, which are synthesized in 
response to pathogen attack [25-26]. An increasing number of RND-type transporters conferring 
multidrug resistance in plant-associated bacteria have recently been identified, for examples in 
Agrobacterium tumefaciens [27], in Pseudomonas syringae [28], in Erwinia chrysanthemi [29], in 
Bradyrhizobium japonicum [30], in Xanthomonas oryzae [31], and in Ralstonia solanacearum[32]. 
E. amylovora, a member of Enterobacteriaceae, is the causal agent of fire blight on apple and 
various other Rosaceae. Burse et al. [33] demonstrated that AcrB played an important role in virulence 
of E. amylovora and was required for resistance towards diverse plant phytoalexins as well as for 
successful colonization of the host plant. Recently, mutational analysis showed that TolC is also 
indispensable for virulence and bacterial in planta multiplication by mediating resistance towards 
phytoalexins through its exclusive interaction with AcrAB in E. amylovora [34]. 
Herein, knock-out mutants of E. amylovora and E. coli defective in acrAB or tolC, respectively, 
were complemented with respective homologous or heterologous alleles in order to investigate 
whether components of the two systems can be exchanged thereby altering substrate spectra and to 
determine potential ecological niche-mediated adaptations for both bacterial species.     
2. Results and Discussion 
2.1. Bioinformatics approach 
A BLAST search with the genome sequence of E. amylovora Ea237 
(http://www.sanger.ac.uk/projects/E.amylovora) using the amino acid sequence of AcrB from E. coli 
K12 strain DH10B (accession number YP-001729367) as query identified six homologous sequences 
in the genome of Ea237. At the amino acid sequence level, the respective predicted E. amylovora 
proteins showed the following identities (similarities given in brackets): AcrB with 83% (92%), AcrD 
with 78% (89%), MdtB with 81% (90%), MdtC with 73% (86%), and two MdtB- and MdtC-like 
proteins with 63% (79%) and 56% (73%), respectively [35-36].  
Additionally, the respective E. amylovora homologues of the E. coli membrane fusion protein AcrA 
and the transcriptional repressor AcrR showed 73% and 62% identity (83% and 79% similarity), 
respectively [13,35]. A BLAST search using the amino acid sequence of TolC from E. coli revealed 
presence of only one TolC homologue in E. amylovora with 77% identity (86% similarity) suggesting 
a high degree of conservation of genomic arrangements between the two enterobacterial species. 
 
2.2. Susceptibility of E. coli and E. amylovora towards antimicrobial compounds 
 
     The susceptibility of the wild types and respective single mutants with deletions in acrB or tolC of 
E. coli and E. amylovora to a variety of antimicrobial compounds were examined in complex and 
minimal medium using the determination of minimal inhibitory concentrations (MIC) (Tables 1-4). 
Double mutants defective in acrB and tolC served as negative controls. Different plant-derived 
antimicrobial compounds, which were previously reported to be substrates for E. amylovora AcrAB-
TolC [33-34], bile salt as a reported substrate for AcrAB-TolC in E. coli [37], and various other Int. J. Mol. Sci. 2009, 10                 
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antimicrobials were tested. Single deletion of acrB or tolC and simultaneous deletion of acrB and tolC 
resulted in increased susceptibility of E. coli mutants toward all tested plant-borne antimicrobial 
compounds. The respective MICs for phloretin, (+)-catechin, naringenin, quercetin,  and berberine 
decreased more than 4-fold, 4-fold, 8-fold, 8-fold, and 16-fold, respectively, in complex medium and 
about 8-fold in minimal medium except for berberine, for which the MICs were reduced about 64-fold, 
as compared to E. coli wild type MICs (Tables 1 and 3).  Similarly, E. amylovora mutants defective in 
acrB or tolC and the double mutant exhibited 4-fold, 8-fold, 8-fold, 16-fold, and 32-fold decreased 
MICs towards (+)-catechin, phloretin, naringenin, quercetin, and berberine, respectively, in both, 
complex and minimal medium (Tables 2 and 4). Consequently and despite of the fact that E. coli is 
neither a plant pathogen nor usually exposed to plant-borne chemical defense reactions, AcrAB-TolC 
of this human-associated bacterium can exclude phytoalexins. This interesting result further 
substantiated the broad substrate spectrum of this MDE system [14,38] and is in line with the idea that 
intestinal microbes are constantly challenged by toxic substances derived from plant-borne diet in 
mammals [39]. Alternatively, our result might indicate a high degree of phylogenetically conserved 
functionality of the AcrAB-TolC complex among enterobacteriaceae.  
Table 1. Susceptibility of Escherichia coli strains to different compounds in complex 
medium MHB. 
Compounds   MIC 
a (µg/mL) 
TG1  ΔacrB  ΔtolC  ΔacrB 
ΔtolC 
ΔacrB 
(Ea acrAB)
ΔacrB 
(Ec acrAB) 
ΔtolC 
(Ea tolC) 
ΔtolC 
(Ec tolC) 
Phloretin >1000  250  125  125 >1000 >1000 >1000 >1000 
Naringenin >1000  125  125  125 >1000 >1000 >1000 >1000 
(+)-Catechin >1000  250 250 250 >1000 >1000 >1000 >1000 
Quercetin >1000  125  62.5  62.5 >1000  >1000 >1000 >1000 
Berberine >1000  62.5  62.5  62.5  >1000  >1000  >1000  >1000 
Bile salt  >1000  15.6  15.6  15.6 >1000  >1000 >1000 >1000 
Acriflavine 15.6  1.56  1.56  1.56  31.2 31.2  15.6  15.6 
Novobiocin 1000  50  50  25  >1000  >1000  1000  1000 
Ampicillin 31.2  6.25  6.25  6.25  31.2  31.2  31.2  31.2 
Cefoperazone 12.5  0.75  0.75  0.75  6.25  6.25  6.25  12.5 
Mitomycin   50  2.5  1.25  1.25  50  100  50  50 
Tetracycline 3.12  0.15  0.075  0.075  3.12  3.12 3.12 3.12 
Nalidixic acid  10  1  1  1  10  10  5  10 
Norfloxacin 0.62  0.062  0.062  0.062  0.62  0.62 0.62 1.25 
Ciprofloxacin 0.62  0.062  0.062  0.062 0.62  0.62  0.62  0.62 
Amikacin 1.25  1.25  0.15  0.15  1.25  1.25  2.5  1.25 
Tobramycin   2.5  1.25  0.15  0.075  2.5  5  5  5 
Erythromycin 12.5  3.12  0.62  0.15  12.5  25  25  12.5 
Rifampin 12.5  1.56  0.31  0.075  25 25  12.5  25 
Jasmone 500  125  31.2  7.5  500  1000  1000  250 
Clotrimazole 62.5  6.25  1.56  0.31 62.5  31.2  31.2  62.5 Int. J. Mol. Sci. 2009, 10                 
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Table 1. Cont. 
SDS 1000  100  100  100  1000  1000  1000  1000 
Ethidium bromide  250  15.6  15.6  15.6  250  500  125  250 
Crystal violet  12.5  2.5  2.5  2.5  12.5  25  12.5  12.5 
  a MIC determination by the dilution assay was repeated at least three times in each case thereby confirming       
consistencies of MIC values. 
Table 2. Susceptibility of Erwinia amylovora strains to different compounds in complex 
medium MHB. 
Compounds   MIC 
a (µg/mL) 
  1189  ΔacrB  ΔtolC  ΔacrB 
ΔtolC 
ΔacrB 
(Ea acrAB)
ΔacrB 
(Ec acrAB)
ΔtolC 
(Ea tolC) 
ΔtolC 
(Ec tolC)
Phloretin  1000 125 125 125 >1000  >1000 >1000  >1000 
Naringenin 1000  62.5  125  125  1000  1000  1000  1000 
(+)-Catechin >1000  125  250  250 >1000 >1000  >1000  >1000 
Quercetin 1000  62.5  62.5  125  >1000  >1000  1000  1000 
Berberine  1000 31.2 31.2 31.2  1000  1000  1000  1000 
Bile salt  >1000  125  125  125 >1000 >1000  >1000  >1000 
Acriflavine  15.6 1.56 3.12 3.12  31.2  31.2  31.2  31.2 
Novobiocin  62.5 1.56 1.56 1.56  62.5  31.2  62.5  62.5 
Ampicillin  62.5 6.25 12.5 6.25  62.5  62.5  62.5  31.2 
Cefoperazone 12.5  3.12  3.12  3.12 12.5  25  12.5 12.5 
Mitomycin    6.25 0.31 0.62 0.62  12.5  25  12.5  12.5 
Tetracycline  6.25 0.62 0.62 0.62  12.5  6.25  6.25  12.5 
Nalidixic  acid  1.25 0.12 0.12 0.12  1.25  0.62  1.25  1.25 
Norfloxacin  0.62  0.031 0.062 0.062  0.62  0.62  0.62  0.62 
Ciprofloxacin  0.62  0.062 0.062 0.062  0.62  0.62  0.62  0.62 
Amikacin 2.5  2.5  0.31  0.31  1.25  1.25  2.5  1.25 
Tobramycin    2.5  1.25 0.075 0.15  2.5  2.5  2.5  5 
Erythromycin  12.5 3.12 0.62 0.15  12.5  25  25  12.5 
Rifampin 12.5  3.12  0.31  0.075  25  12.5  12.5  25 
Jasmone  250  62.5 15.6 3.12  250  250  500  500 
Clotrimazole 15.6  3.12  0.15  0.075  62.5 31.2  62.5  31.2 
SDS  >1000  100 100 100 >1000  >1000 1000 1000 
Ethidium  bromide  31.2 3.12 3.12 3.12  62.5  62.5  62.5  62.5 
Crystal  violet  3.12 0.62 0.62 0.62  3.12  3.12  3.12  6.25 
           a MIC determination by the dilution assay was repeated at least three times in each case thereby confirming 
       consistencies of MIC values. 
 
The three tested E. amylovora mutants were about 8-fold more sensitive to bile salt as compared to 
the wild type regardless of the used medium. In contrast, the three E. coli mutants exhibited a 64-fold 
increased sensitivity to bile salt in both media in comparison to the wild type (Tables 1-4). This result 
clearly demonstrated that E. amylovora may possess an alternative MDE pump during the 
detoxification process for bile salts such as demonstrated for EefABC in Enterobacter aerogenes [40]. Int. J. Mol. Sci. 2009, 10                 
 
 
634
It remained obscure why the E. coli mutants exhibited higher susceptibilities towards bile salt since 
one might have assumed a better adaptation of this bacterium to this toxic compound [41]. 
Table 3. Susceptibility of Escherichia coli strains to different compounds in minimal 
medium AMM2. 
Compounds   MIC 
a (µg/mL) 
TG1  ΔacrB  ΔtolC  ΔacrB 
ΔtolC 
ΔacrB 
(Ea acrAB)
ΔacrB 
(Ec acrAB) 
ΔtolC 
(Ea tolC) 
ΔtolC 
(Ec tolC) 
Phloretin >1000  250  125  250 >1000 >1000 >1000 >1000 
Naringenin >1000  125  250  125 >1000 >1000 >1000 >1000 
(+)-Catechin >1000  125  125  62.5 >1000  >1000 >1000 >1000 
Quercetin >1000  125  125  62.5 >1000  >1000 >1000 >1000 
Berberine  >1000  62.5 62.5 62.5  >1000  >1000  >1000  >1000 
Bile salt  >1000  15.6  15.6  15.6 >1000  >1000 >1000 >1000 
Acriflavine  7.5 1.56 1.56 1.56  7.5  15.6  7.5  15.6 
Novobiocin 1000  100  100  50  >1000  >1000  >1000  1000 
Ampicillin  15.6 3.12 6.25 3.12  31.2  31.2  31.2  31.2 
Cefoperazone  6.25 0.62 0.62 0.62  6.25  6.25  6.25  12.5 
Mitomycin    12.5  1.5 1.5 1.5  12.5  12.5  12.5  12.5 
Tetracycline 1.56  0.15  0.15  0.075  1.56  1.56 3.12 3.12 
Nalidixic  acid  6.25 1.25 0.62 0.62  12.5  6.25  12.5  12.5 
Norfloxacin  0.62 0.062 0.062 0.062  0.62  0.62  0.62  1.25 
Ciprofloxacin  0.62 0.015 0.062 0.062  0.62  0.62  0.62  0.62 
Amikacin 1.25  1.25  0.15  0.075  1.25  1.25  2.5  1.25 
Tobramycin   1.25  1.25  0.075  0.075  2.5  5  5  5 
Erythromycin  25 3.12 0.62 0.15  12.5  25  12.5  12.5 
Rifampin 12.5  1.56  0.31  0.075  25 25  12.5  25 
Jasmone 500  125  31.2  7.5  1000  500  1000  500 
Clotrimazole  62.5 6.25 1.56 0.31  125  62.5  125  62.5 
SDS  500 100 100 100  500  500  500  1000 
Ethidium bromide  125 1.56 1.56 1.56  250  250  125  250 
Crystal  violet  6.25 1.25 0.62 0.62  6.25  6.25  6.25  12.5 
 a MIC determination by the dilution assay was repeated at least three times in  each  case  thereby  confirming      
consistencies of MIC values. 
 
In contrast to the mutants of E. amylovora, growth medium-dependent susceptibility towards the 
following group of antimicrobials was observed for the three E. coli mutants: acriflavine, novobiocin, 
ampicillin, cefoperazone, mitomycin, tetracycline, nalidixic acid, norfloxacin, ciprofloxacin, SDS, 
ethidium bromide, and crystal violet. For those substances the E. coli wild type was about 5- to 20-fold 
more resistant as compared to the mutants in complex medium but only 4- to 10-fold more resistant in 
minimal medium (Tables 1 and 3). E. amylovora mutants were 5- to 40-fold more sensitive to those 
compounds as compared to their wild type regardless of the used growth medium (Tables 2 and 4). 
These apparently conflicting results might be rather due to the auxotropic status of E. coli TG1 and its 
general physiological fitness in minimal medium [42] than due to substrate specificity alterations.  Int. J. Mol. Sci. 2009, 10                 
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 The MICs of the aminoglycosides amikacin and tobramycin for the acrB mutants of E. coli and E. 
amylovora did not differ from those determined for the wild type strains suggesting that those 
substances did not act as substrates of AcrB. In contrast, the same substances caused 8-fold and 16-
fold increased sensitivities for the tolC mutants and the acrB / tolC double mutants of both species in 
complex and minimal medium, respectively. It was previously demonstrated that TolC additionally to 
its function with AcrB could specifically interact with another RND-type transporter of E. coli termed 
AcrAD in extruding a variety of hydrophilic aminoglycosides from the periplasm and   
cytoplasm [38,43].  
Table 4. Susceptibility of Erwinia amylovora strains to different compounds in minimal 
medium AMM2. 
Compounds   MIC 
a (µg/mL) 
1189  ΔacrB  ΔtolC  ΔacrB 
ΔtolC 
ΔacrB 
(Ea acrAB)
ΔacrB 
(Ec acrAB) 
ΔtolC 
(Ea tolC) 
ΔtolC 
(Ec tolC) 
Phloretin  1000  125 125 125 >1000  >1000  >1000 >1000 
Naringenin  1000  62.5  125  125  1000 1000 1000  1000 
(+)-Catechin  >1000  125 250 250 >1000  >1000  >1000 >1000 
Quercetin 1000  62.5  62.5  125  >1000  >1000  1000  1000 
Berberine  1000  31.2 31.2 31.2  1000  1000  1000  1000 
Bile salt  >1000  125  125  125 >1000 >1000 >1000  >1000 
Acriflavine  15.6 1.56 3.12 3.12  31.2  31.2  31.2  31.2 
Novobiocin  62.5 1.56 1.56 1.56  62.5  31.2  62.5  62.5 
Ampicillin  62.5 6.25 12.5 6.25  62.5  62.5  62.5  31.2 
Cefoperazone  12.5 3.12 3.12 3.12  12.5  25  12.5  12.5 
Mitomycin    6.25 0.31 0.62 0.62  12.5  25  12.5  12.5 
Tetracycline  6.25 0.62 0.62 0.62  12.5  6.25  6.25  12.5 
Nalidixic  acid  1.25 0.12 0.12 0.12  1.25  0.62  1.25  1.25 
Norfloxacin  0.62 0.031 0.062 0.062  0.62  0.62  0.62  0.62 
Ciprofloxacin  0.62 0.062 0.062 0.062  0.62  0.62  0.62  0.62 
Amikacin  1.25  1.25  0.075  0.075  1.25 2.5 1.25  1.25 
Tobramycin    2.5  2.5  0.15  0.15  2.5 2.5 2.5  2.5 
Erythromycin  25 6.25 1.25 0.31  12.5  25  12.5  12.5 
Rifampin 6.25  1.56  0.15  0.075  25 25  12.5  25 
Jasmone  125  31.2 7.5 1.56  250  250  250  250 
Clotrimazole  31.2 6.25 3.12 0.31  62.5  31.2  31.2  62.5 
SDS  >1000  100 100 100 >1000  >1000  1000  1000 
Ethidium bromide  31.2 3.12 3.12 3.12  62.5  62.5  62.5  62.5 
Crystal  violet  3.12 0.62 0.62 0.62  3.12  3.12  3.12  6.25 
  a MIC determination by the dilution assay was repeated at least three times in each case thereby confirming      
consistencies of MIC values. 
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Additive effects in the reduction of MICs due to simultaneous disruption of acrB and tolC 
regardless of the used species and medium could be observed for erythromycin, rifampin, jasmone, 
and clotrimazole. The MIC values of the acrB mutants for these compounds were reduced 4- to 10-
fold. In contrast, respective MIC values declined in the tolC mutants about 10- to 40-fold. 
Susceptibilities increased 64- to 200-fold in the acrB / tolC double mutant of E. coli and about 80-fold 
in the respective E. amylovora double mutant (Tables 1-4), suggesting that outer membrane-bound 
TolC might interact with additional partners during the extrusion of these compounds. Chollet et al. 
[44] demonstrated that telithromycin, a ketolide comparable to macrolides, is not a substrate for 
AcrAB-TolC but it is efficiently recognized by another PAβN-sensitive system pump. Elkins and 
Mullis [14] showed that the MFS-type tripartite system, EmrAB-TolC, of E. coli has the extraordinary 
capacity to transport mammalian steroid hormones. This transporter is ‘silent’ under normal laboratory 
conditions and its contribution to MDE resistance towards steroids and macrolides is masked by the 
overlapping substrate repertoire of the AcrAB-TolC system [14]. Likewise, MacAB of E. coli is 
cooperating with TolC in exporting macrolides [45]. The herein observed additive effects in MIC 
reduction may be related to presence of EmrAB in both, E. coli and E. amylovora. A BLAST search in 
the genome sequence of E. amylovora 237 revealed presence of an EmrB homolog with 83% identity 
and 92% similarity but no MacB homologs.  
2.3. Allelic exchange analysis of AcrAB-TolC in E. amylovora and E. coli 
 
As expected and in line with our previously published data [33-34], the MIC phenotypes of acrB 
and  tolC single mutants of E. amylovora could be fully restored to wild type levels with clones 
containing E. amylovora acrAB and tolC, respectively. Without any exceptions, the same results were 
obtained when respective E. coli mutants were complemented with cloned E. coli acrAB and tolC 
genes (Tables 1-4). Next, single mutants of E. amylovora were transformed to carry acrAB or tolC, 
respectively, derived from E. coli and vice versa. Thus it was tested whether or not the individual 
components of the AcrAB-TolC complex from the two enterobacterial species can interact without 
interferences. Interestingly, all thus generated transformants showed fully restored wild type MIC 
phenotypes (Tables 1-4), suggesting that the AcrAB-TolC efflux systems of E. coli and E. amylovora 
are truly interchangeable despite of the variable ecological niches both organisms occupy. The results 
furthermore allowed the conclusion that the divergence in micro-ecological adaptation had not led to 
specialized MDE pumps with respect to AcrAB-TolC but that this system is multifunctional and 
ancestral. This confirmed an earlier study, in which MDE pumps from Ralstonia solanacearum were 
used to complement respective E. coli mutants [32]. Our data are also in agreement with those from 
Tikhonova et al. [46] and Bokma et al. [47], who reported on the functionality of AcrB-MexB hybrid 
proteins and the directed evolution-based adaptation of E. coli TolC to the MexAB translocase of 
Pseudomonas aeruginosa. The later authors generated active hybrid pumps by challenging a library of 
mutated and shuffled TolC variants to adapt to the non-cognate P. aeruginosa MexAB system. The 
obtained analysis of amino acid substitutions in TolC revealed that adaptation to the heterogenous 
efflux pump was conferred by substitutions of amino acyl residues located in the lower α-helical barrel 
in the periplasmic equatorial domain and the entrance coiled coils of TolC [47]. Protein sequence 
alignment of E. coli TolC versus that of E. amylovora TolC revealed that all the substituted amino acid Int. J. Mol. Sci. 2009, 10                 
 
 
637
residues reported by Bokma et al. [47] are conserved in both enterobacterial species (data not shown) 
thus by further substantiating a tight phylogenetic relatedness of AcrAB-TolC in E. coli and   
E. amylovora.  
Interestingly, any complementation led to MIC wild type level of the species, into which the 
heterologous alleles were transferred. These results underscore the principle that antibiotics resistance 
is determined by both, efflux and outer membrane permeability. In this context, it is remarkable that 
permeability for many of the tested compounds differed between E. amylovora and E. coli. 
2. 4. In planta virulence assays 
 
Previously it was demonstrated that E. amylovora mutants with defects in acrB and tolC were not 
causing fire blight symptoms on apple plants and showed significantly reduced in planta survival [33-
34]. These mutants could be complemented by plasmid-borne homogenous alleles. Since heterogenous 
alleles of acrB and tolC led to wild type MIC values in the respective E. amylovora mutants in vitro, it 
was tested whether acrB and tolC of E. coli could restore virulence of E. amylovora acrB and tolC 
single mutants. Respective E. amylovora transformants were inoculated to apple plants using the 
mutants and the wild type as controls. Plant shoot tips were inoculated with defined numbers of 
bacterial cells by the so-called prick technique [48], which mimics the natural infection process. 
Typical fire blight symptoms in form of shepherd’s crook-like bending of the shoot tip after one week 
post inoculation as well as ooze formation and necrosis after three weeks post inoculation were 
induced by E. amylovora wild type and the E. amylovora mutants carrying acrB or tolC from E. coli in 
all 15 plants inoculated per strain without exceptions (Figure 1).  
Figure 1. Pathogenicity assay on apple plants. Shoot tips were inoculated with 5 µL of 
1 x 10
7 CFU/mL bacterial suspensions. Disease symptoms such as the typical 
‘shepherd’s crook’ formation and wilting developed on plants inoculated with E. 
amylovora wild type after one week of inoculation.  
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In contrast, the non-complemented mutants did not cause any disease symptoms thus confirming 
their previously reported in planta phenotypes [33-34].  All inoculated plants showed the same lack of 
symptom development. Interestingly, for the first time these results led to the conclusion that 
enterobacterial AcrAB-TolC hybrids consisting of mixed components from a plant pathogen and an 
intestinal species are sufficient to effectively combat plant defense reactions. These results furthermore 
substantiated our in vitro findings and showed that AcrB and TolC of E. coli and E. amylovora are 
apparently fully interchangeable. The herein obtained data are in line with recent findings of 
Krishnamoorthy et al. [49], who reported that the replacement of E. coli AcrB with its close homolog, 
MexB, from Pseudomonas aeruginosa formed a partially functional MDE system, AcrA-MexB-TolC, 
in vitro and that certain single amino acid substitutions in AcrA and MexB, respectively, were 
sufficient to render this MDE hybrid fully functional. The data obtained herein demonstrated that 
complementation of acrAB or tolC of a plant pathogen by respective alleles derived from E. coli can 
restore full virulence. In this respect, our results are in advancement towards those of Brown et al. 
[32], who had demonstrated that MDE components of the plant pathogen R. solanacearum were 
successfully complementing E. coli mutants in vitro.  
3. Experimental  
3.1. Bacterial strains, plasmids, and growth conditions 
 
     Bacterial strains and plasmids used in this study were listed in Tables 5 and 6. E. coli strains were 
routinely maintained at 37°C on Luria-Bertani (LB) medium, and E. amylovora strains were cultured 
at 28 °C on LB medium or asparagine minimal medium 2 (AMM2).  
Table 5. E. coli and E. amylovora strains used in this study.  
Strain Relevant  characteristics  Reverence 
or source 
E. coli  
DH5α  
 
supE44 ∆lacU169 (φ80 lacZ ∆M15) hsdR17 recA1 endA1 
gyrA96 thi-1 
[42] 
S17-1 λ-pir  λ-pir lysogen of S17-1  [50] 
TG1  subE hsd∆5 thi ∆(lac-proAB) F`[traD36 proAB
+ lacI
q lacZ 
∆M15] 
[42] 
KAM3  acrB mutant of TG1  [51] 
TG1-1 Gm
r, tolC mutant of TG1  This study 
KAM3-1 Gm
r, tolC mutant of KAM3   This study 
E. amylovora 
1189 
 
wild type  
 
GSPB
a 
1189-3 Km
r, acrB mutant of 1189   [33] 
1189-25 Gm
r, tolC mutant of 1189  [34] 
1189-3-3 Km
r, Gm
r, acrB tolC mutant of 1189  [34] 
a GSPB, Göttinger Sammlung phytopathogener Bakterien, Göttingen, Germany. Int. J. Mol. Sci. 2009, 10                 
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Table 6. Plasmids used in this study. 
Plasmid  Relevant characteristics  Reference or 
source  
pGEM-T 
Easy 
Ap
r, ColE1 origin  Promega  
pNK14 Ap
r, 1851-bp PCR fragment containing E. coli  tolC in 
pGEM-T Easy  
This study 
pBBR1MCS-
5 
Gm
r, Source of the Gm
r cassette  [52] 
pNK15 Ap
r, replacement of a 597-bp BssHII fragment from the 
tolC gene of pNK14 with a 1246-bp fragment containing 
the Gm
r cassette from pBBR1MCS-5  
This study 
pCAM-MCS Ap
r, pCAM140-derivative without mini-Tn5, contains the 
MCS of pBluescript II SK (+) 
[33] 
pNK16 Ap
r, Gm
r, 2500-bp EcoRI fragment from pNK15 ligated 
into EcoRI-linearized pCAM-MCS 
This study 
pBBR1MCS Cm
r, ColE1 origin  [52] 
pNK17 Cm
r, 2012-bp SpeI-SacI fragment carrying tolC of E. coli 
cloned in pBBR1MCS in opposite direction of lacZ 
This study 
pNK18 Cm
r, 4701-bp HindIII-SacI fragment carrying acrAB of 
E. coli cloned in pBBR1MCS in opposite direction of lacZ 
This study 
pNK19 Cm
r, 5596-bp HindIII-SacI fragment carrying acrAB-R of 
E. coli cloned in pBBR1MCS in opposite direction of lacZ 
This study 
pNK7 Cm
r, 2630 bp SpeI-SacII fragment carrying tolC of 
E. amylovora cloned in pBBR1MCS in opposite direction 
of lacZ 
[34] 
pNK8 Cm
r, 4917 bp SpeI-SacI fragment carrying acrAB of 
E. amylovora cloned in pBBR1MCS in opposite direction 
of lacZ 
[34] 
pNK20 Cm
r, 5746 bp SpeI-SacI fragment carrying acrAB-R of 
E. amylovora cloned in pBBR1MCS in opposite direction 
of lacZ 
This study 
 
AMM2 has the following composition (per liter of deionized water): fructose, 10 g; L-asparagine, 
4 g; Na2HPO4 × 7 H2O, 12.8 g; K2HPO4, 3 g; NaCl, 3 g; MgSO4 × 7 H2O, 0.2 g; nicotinic acid, 0.25 g; 
thiamine, 200 µg. E. coli DH5α was used as cloning host. Cultures were supplemented with 50 µg/mL 
ampicillin (Ap), 25  µg/mL chloramphenicol (Cm), 2 µg/mL gentamycin (Gm), and 25  µg/mL 
kanamycin (Km) when necessary. Bacterial growth was monitored using a spectrophotometer   
(OD at 600 nm). Int. J. Mol. Sci. 2009, 10                 
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3.2. Generation of tolC mutants in E. coli  
 
     E.  coli  tolC-deficient mutants TG1-1 and KAM3-1 were generated by marker exchange 
mutagenesis as follows. An 1851-bp fragment located in the tolC gene was PCR-amplified from 
E. coli TG1 using primer pair Ec-tolC-del-Fwd and Ec-tolC-del-Rev (Table 7). The PCR product was 
cloned into pGEM-T Easy (Promega, Mannheim, Germany) yielding plasmid pNK14. A 597-bp 
BssHII fragment of pNK14 located in the tolC gene was replaced by a 1246-bp BssHII fragment 
containing the gentamycin resistance cassette (Gm
r) derived from pBBR1MCS-5 [52] yielding the 
5515-bp plasmid pNK15. A 2500-bp EcoRI fragment cut from pNK15 was ligated into EcoRI-digested 
pCAM-MCS [33] yielding the final tolC replacement plasmid pNK16 (6207 bp). E. coli S17-1 λ-pir 
was used as host for the suicide plasmid. Plasmid pNK16 was transferred via electroporation into 
electro-competent cells of E. coli TG1 and its acrB mutant KAM3, which subsequently were grown at 
37°C for 1 h in SOC broth and plated on LB containing gentamycin. Putative mutants were screened 
for homologous recombination events by checking their antibiotics resistance. To confirm the altered 
genotypes, PCR amplification of tolC using primers Ec-tolC-del-Fwd and Ec-tolC-del-Rev (Table 7) 
was carried out yielding a 2500-bp fragment for the tolC mutants as opposed to the presence of an 
1851-bp fragment for the wild type. 
Table 7. Oligonucleotide primers used in this study. 
Primer  Nucleotide sequence (5'-3')* 
Ec-tolC-del-Fwd AACTTCATCACGCACTGG 
Ec-tolC-del-Rev TTGCTGAACGACTGGTGC 
Ec-tolC-com-Fwd GATGAGCTCAACTTCATCACGCACTGG 
Ec-tolC-com-Rev CGAACTAGTATAGAGGATGGCTGGTCG 
Ec-acr-com-Fwd CGATAAGCTTGAGATCCTGAGTTGGTGG 
Ec-acr-com-Rev- GCTAGAGCTCAGCGAGGTGGATGATACC 
Ec-acr-com-Rev+ GCTAGAGCTCGTATCTGTCAGATCCTGC 
Ea-acr-com-Fwd+ CGAGAGCTCGAATACGGTTCTCTGAGC 
Ea-acr-com-Rev GATACTAGTCGGTATAGTAAACGTGCG 
*Restriction sites incorporated into primers are underlined: AAGCTT, HindIII; GAGCTC, SacI; and 
ACTAGT, SpeI.  
3.3. Complementation of mutants  
      
The plasmid for complementation of the tolC-deficient E. coli was generated as follows: a 2012-bp 
fragment containing the tolC region was PCR amplified from E. coli TG1 using primer pair Ec-tolC-
com-Fwd and Ec-tolC-com-Rev (Table 7). The PCR fragment was cloned into SpeI-SacI-digested Int. J. Mol. Sci. 2009, 10                 
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pBBR1MCS [52] yielding the E. coli tolC complementation plasmid pNK17 (6719 bp). Plasmid pNK7 
[34] was used to complement the tolC mutant of E. amylovora.  
The plasmids for complementation of the acrAB- and acrABR-deficient  E. coli mutants  were 
generated as follows: 4701-bp and 5596-bp fragments containing the acrAB and acrAB-R regions, 
respectively, were PCR amplified from E. coli TG1 using the primer pairs Ec-acr-com-Fwd/Ec-acr-
com-Rev- and Ec-acr-com-Fwd/Ec-acr-com-Rev+ (Table 7). The PCR fragments were cloned into 
HindIII-SacI-digested pBBR1MCS [52] yielding the E. coli acrAB complementation plasmid pNK18 
(9408 bp) and the E.coli acrAB-R complementation plasmid pNK19 (10303 bp).  
     The plasmid for complementation of the acrABR-deficient E. amylovora mutant was generated as 
follows: a 5746-bp fragment containing the acrAB-R region was PCR amplified from E. amylovora 
1189 using the primer pair Ea-acr-Com-Fwd+ and Ea-acr-Com-Rev (Table 7). The PCR fragment was 
cloned into SpeI-SacI digested pBBR1MCS [52] yielding the E. amylovora acrAB-R complementation 
plasmid pNK20 (10453 bp). Plasmid pNK8 [34] was used to complement the acrB mutant   
of E. amylovora. 
3.4. Drug susceptibility tests 
     
The minimal inhibitory concentrations (MIC) were determined by a twofold dilution assay in 
Mueller-Hinton broth (MHB) (Becton Dickinson, Heidelberg, Germany) and AMM2, respectively. All 
tests were done in triplicate following the National Center for Clinical Laboratory Standards 
recommendations [53]. Chemicals were obtained from Sigma-Aldrich (Taufkirchen, Germany). E. 
amylovora strains were incubated at 28 °C, and E. coli strains were incubated at 37 °C. The MIC was 
defined as the lowest concentration of an antibiotic that completely stopped visible cell growth. 
Bacterial growth was examined by visual and photometric inspection after 24 h of incubation. 
3.5. Plant materials and pathogenicity assay on apple 
      
Apple plants (rootstock Malus MM106) were grown in a light chamber at 20 to 25 °C, 60% 
humidity, with a 12-h photoperiod (15,000 lux). E. amylovora strains were grown on LB agar plates 
for 48 h, re-suspended in sterile 0.9% NaCl solution, and diluted to a cell density of 1 x 10
7 CFU/mL 
for inoculation. Apple plants were inoculated by the prick technique as described previously [48]. 
Each bacterial strain was inoculated into shoots of five individual plants by placing 5 µL of bacterial 
suspensions onto each wound on the shoot tip. The experiment was repeated three-fold. Plants were 
monitored for symptom development daily.  
4. Conclusions 
The AcrAB-TolC system is widely distributed among Gram-negative bacteria and represents a 
bacterial defense system not only against antibiotics, but also against numerous structurally unrelated 
molecules present in different ecological niches, such as bile salt in the intestinal tract and 
phytoalexins in plants. Herein it was demonstrated that components of the MDE system, AcrAB-TolC, 
of two different enterobacterial species are interchangeable despite of the significantly diverse 
ecological niches, in which both species live. On one hand, this might reflect the broad flexibility of Int. J. Mol. Sci. 2009, 10                 
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this important bacterial antibiotics resistance determinant. On the other hand, these results suggested 
that habitat-borne divergence of antibiotics exposure did not lead to significant structural 
modifications of this MDE system during evolution. For the first time, it was demonstrated that 
respective E. coli genes can restore full virulence to E. amylovora mutants defective in the genes 
encoding for AcrAB-TolC.     
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